Navigation Links
Researcher tests drug's impact on neurological disease affecting women
Date:6/7/2011

EAST LANSING, Mich. A rare but increasingly more common disease striking overweight, younger women is the focus of a clinical trial at Michigan State University, where an osteopathic physician is testing the effectiveness of a certain drug against a potentially blindness-causing ailment.

Idiopathic intracranial hypertension, known as IIH or pseudo-tumor cerebri, is a neurological disease resulting in increased pressure around the brain, specifically in the absence of a tumor. Symptoms include severe headaches, nausea and double vision, and if left untreated, IIH can lead to vision loss and blindness.

Eric Eggenberger, professor and associate chairperson in MSU's Department of Neurology and Ophthalmology, is leading a clinical trial to test the ability of a commonly used diuretic known as acetazolamide in reducing or reversing vision loss in patients with IIH. Diuretics are drugs that increase the rate of urination.

"While weight loss is always recommended for women suffering from IIH, many other treatments are used to battle the disease by decreasing pressure around the brain," said Eggenberger, a member of MSU's HealthTeam.

"The problem is, none of these strategies have been verified by clinical trials, and there is no compelling evidence on which treatments work best and why."

In addition, he said, more evidence is needed on the potential side effects of drugs such as acetazolamide.

Though IIH is rather rare, affecting only 22 out of every 100,000 Americans, its incidence rate is rising in parallel with the obesity epidemic sweeping the nation. The cause of the endocrine-based disease is not known, but it usually affects women of child-bearing age who are overweight or obese. It is rare in post-menopausal women and men of all ages.

The clinical trial run by Eggenberger at MSU has three main goals: establish evidence-based treatment strategies to restore and protect vision, follow patients for up to four years to observe long-term treatment outcomes and help determine the cause of IIH.

All patients in the trial will receive Web- and phone-based diet information to help subjects lose weight. The study also will randomly assign patients to one of two groups: those receiving acetazolamide and those receiving a placebo. Patients will be monitored for six months to test the impact of the drug.

Subjects also will undergo genetic screening, specifically looking at vitamin A and genes that may be risk factors for IIH. That analysis could help researchers with the frustrating task of pinpointing what causes the disease, Eggenberger said.


'/>"/>

Contact: Jason Cody
codyja@msu.edu
517-432-0924
Michigan State University
Source:Eurekalert  

Related medicine news :

1. A decade dedicated to breast cancer care advocacy garners ASCO Award for researcher
2. Researchers discover biochemical weakness of malaria parasite -- vaccine to be developed
3. Researchers find that inhibiting microRNAs may help prevent degenerative eye disorders
4. CWRU researcher studies ways to help teens overcome fears and stigmas of mental illness
5. Calorie-burning brown fat is a potential obesity treatment, researchers say
6. City of Hope researchers to present rectal cancer, palliative care, benchmarking studies at ASCO
7. U of Alberta researchers hoping to stop heart disease in cancer patients before it starts
8. U of A researchers hope to stop heart
9. UofL researchers uncover mechanism in saliva production
10. UF researchers suggest cholera vaccination strategies for Zimbabwe
11. Researchers characterize epigenetic fingerprint of 1,628 people
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researcher tests drug's impact on neurological disease affecting women
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology: